Intravenous immunoglobulin as a therapeutic option for patients with worsening COVID-19 under rituximab

Severe cases of the new COVID-19 are being reported in immunosuppressed patients. The risk seems to depend on the type of immunosuppressive agents used and it is particularly important in patients under the long-lasting effect of rituximab. Information regarding the best therapeutic approach to thes...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasconcelos, Joana, Portugal, Rita, Torres, Rita, Falcão, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240564/
https://www.ncbi.nlm.nih.gov/pubmed/34183316
http://dx.doi.org/10.1136/bcr-2021-243338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240564/
https://www.ncbi.nlm.nih.gov/pubmed/34183316
http://dx.doi.org/10.1136/bcr-2021-243338

Ejemplares similares